Fig. 5
From: Construction and applications of the EOMA spheroid model of Kaposiform hemangioendothelioma
The effect of sirolimus on EOMA spheroids. A The proliferation of EOMA spheroids treated with sirolimus for 24 h. B Western blot of expression levels of VEGFC at EOMA spheroids treated with DMSO and sirolimus. C The WB semiquantitative analysis. D Immunohistochemistry staining of VEGFC in normal human skin tissue, KHE tissue, subcutaneous tumors and EOMA spheroids. E The proliferation of EOMA spheroids treated with VEGFC for 24 h. F The intervention of EOMA spheroids treated with sirolimus by VEGFC. G The sprouting of EOMA spheroids treated with sirolimus and VEGFC for 0, 24 and 48 h. H The diameter of EOMA spheroids treated with sirolimus and VEGFC for 0, 24 and 48 h. *P < 0.05, compared to the DMSO or control group (A, C and E). *P < 0.05, compared to the DMSO, #P < 0.05, compared to 50nM sirolimus (F and H). Scale bars = 100 μm